Caribou Biosciences will use MaxCyte’s flow electroporation systems and the company’s ExPERT platform in its allogeneic t-cell therapy programmes.
MaxCyte will receive undisclosed development and approval milestones as well as sales-based payments and “other licensing fees”.
“This important agreement represents another key expansion for MaxCyte, emphasising the value of our technology platform to companies developing pioneering gene-editing and cell therapies,” MaxCyte’s chief executive, Doug Doerfler said in a statement.
“We believe that such programs have high potential to deliver positive clinical impact for patients facing serious and difficult-to-treat diseases."
MaxCyte describes its Flow Electroporation system as being able to deliver “virtually any molecule, to any cell, at any scale”.
Its ExPERT instrument family set takes this a step forward by allowing scientists to carry out complex cell engineering.